Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.51 |
| ▸ | KIT | P10721 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | AXL | P30530 | 2/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12408413 | 0.96 | CSF1R (0.50) | CSF1RKITCYP3A4CYP2C19NTRK1 | |
| SCHEMBL12408023 | 0.89 | CSF1R (0.64) | CSF1RKITCYP3A4CYP2C19NTRK1 | |
| SCHEMBL1859834 | 0.86 | CSF1R (0.59) | CSF1RKITCYP3A4CYP2C19NTRK1 | |
| SCHEMBL12408090 | 0.83 | CSF1R (0.62) | CSF1RKITCYP2C19 | |
| SCHEMBL12482770 | 0.82 | CSF1R (0.56) | CSF1RKITCYP3A4CYP2C19NTRK1 | |
| SCHEMBL12408096 | 0.81 | CSF1R (0.52) | CSF1RKITCYP3A4CYP2C19 | |
| SCHEMBL12408115 | 0.79 | CSF1R (0.54) | CSF1RKIT | |
| SCHEMBL12408018 | 0.77 | CSF1R (0.68) | CSF1RKITCYP3A4CYP2C19NTRK1 | |
| SCHEMBL12408099 | 0.77 | CSF1R (0.47) | CSF1RKITCYP3A4CYP2C19NTRK1 | |
| SCHEMBL12408030 | 0.76 | CSF1R (0.65) | CSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973035-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-07-05 | — | — | US | disclosed |
| US-20080275031-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | ILLIG CARL R | 2008-11-06 | — | — | US | disclosed |
| US-7414050-B2 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, PNCK | CSF1R 249/4885KIT 119/4885CYP3A4 3272/4885 |
| US-20080275031-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, CAMK4 | CSF1R 249/4885KIT 214/4885CYP3A4 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.